New York, May 19, 2026, 07:03 (EDT)
MetaVia Inc. jumped in U.S. pre-market trade Tuesday after saying three late-breaking abstracts for its cardiometabolic drug programs got into the American Diabetes Association’s 2026 Scientific Sessions. The biotech’s shares were at $1.86, up 67.6% from Monday’s close at $1.11, as of 07:02 a.m. EDT, according to MarketScreener. The stock trades on Nasdaq.
The timing is key since the main U.S. stock markets weren’t open yet, and small-cap biotech stocks can jump or drop early on little news. Nasdaq’s posted 2026 holiday list keeps May 19 as a regular session. Memorial Day, May 25, is the next scheduled full-day closure.
MetaVia Inc. said Monday it will have posters at the ADA meeting in New Orleans from June 5-8. Data will cover its obesity drug candidate DA-1726 and vanoglipel (DA-1241), which it is studying in metabolic and liver disease. DA-1726 is described as a GLP-1/glucagon dual agonist, meaning it targets two hormone receptors to cut appetite and increase energy use.
Chief Executive Hyung Heon Kim called the ADA acceptances a “testament to the strength” of MetaVia’s cardiometabolic portfolio. Kim said DA-1726 could “be a differentiated obesity treatment” as the company tries higher doses in a 16-week Phase 1 Part 3 trial. MetaVia Inc.
This is what’s moving the stock: Investors are looking at another data update from an early-stage obesity drug, not reacting to a finished pivotal trial. Phase 1 is still early—mainly about testing safety and tolerability, not showing the drug works well enough for approval.
MetaVia told investors it sees Phase 1 Part 3 titration study results coming in the fourth quarter of 2026. The trial looks at raising doses gradually, which is standard in obesity drug tests to handle side effects as they work toward higher doses.
MetaVia is looking for space in the obesity drug market, up against semaglutide, which Novo Nordisk sells as Wegovy, and tirzepatide, marketed as Zepbound by Eli Lilly. MetaVia said its preclinical mouse work found DA-1726 topped semaglutide for weight loss and was about as effective as tirzepatide and survodutide at reducing weight, with lean body mass preserved.
Analyst calls kept MetaVia active. TipRanks said H.C. Wainwright’s Andrew Fein held his Buy on the stock and left the $20 target unchanged. He said the key is if DA-1726 can break out from other GLP-1 contenders and if results at ADA and EASL will ease some of the risk.
MetaVia’s cash buffer is slim. The company logged a first-quarter net loss of $3.8 million, or 79 cents per share. It said it had $13.7 million in cash and equivalents as of March 31, which it believes will keep it running through the fourth quarter of 2026.
This is also the risk section. MetaVia said in its latest quarterly filing that its losses and negative cash flow have raised “substantial doubt” about staying in business over the next year. The company warned raising new equity might dilute shareholders a lot. MetaVia also said if it can’t raise more money, it may have to slow down or halt some current and planned clinical trials. Securities and Exchange Commission
Tuesday’s jump doesn’t close the book on the drug story for the company. The bigger check is in June with the ADA posters, and after that, MetaVia said it’s aiming to release the next DA-1726 titration data in the fourth quarter.
